Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review
| Autor: | Baki Billah, Nassif Hossain, Lorena Romero, Khurshid Alam, Mohammed J. Alramadan, Afsana Afroz, Dianna J. Magliano |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Social Problems Total cost MEDLINE 030209 endocrinology & metabolism Direct cost Disease CINAHL Type 2 diabetes LMICs Drug Costs Young Adult 03 medical and health sciences Indirect costs 0302 clinical medicine Cost of Illness Environmental health Type 2 diabetes mellitus Humans Hypoglycemic Agents Medicine Disabled Persons 030212 general & internal medicine Developing Countries Poverty health care economics and organizations Aged business.industry lcsh:Public aspects of medicine Health Policy Public health Cost-of-illness Type 2 Diabetes Mellitus lcsh:RA1-1270 Middle Aged medicine.disease Diabetes Mellitus Type 2 Indirect cost Systematic review Income business Research Article |
| Zdroj: | BMC Health Services Research BMC Health Services Research, Vol 18, Iss 1, Pp 1-10 (2018) |
| ISSN: | 1472-6963 |
| DOI: | 10.1186/s12913-018-3772-8 |
| Popis: | Background Diabetes is one of the world’s most prevalent and serious non-communicable diseases (NCDs). It is a leading cause of death, disability and financial loss; moreover, it is identified as a major threat to global development. The chronic nature of diabetes and its related complications make it a costly disease. Estimating the total cost of an illness is a useful aid to national and international health policy decision making. The aim of this systematic review is to summarise the impact of the cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries, and to identify methodological gaps in measuring the cost-of-illness of type 2 diabetes mellitus. Methods This systematic review considers studies that reported the cost-of-illness of type 2 diabetes in subjects aged 18 years and above in low and lower-middle income countries. The search engines MEDLINE, EMBASE, CINAHL, PSYCINFO and COCHRANE were used form date of their inception to September 2018. Two authors independently identified the eligible studies. Costs reported in the included studies were converted to US dollars in relation to the dates mentioned in the studies. Results The systematic search identified eight eligible studies conducted in low and lower-middle income countries. There was a considerable variation in the costs and method used in these studies. The annual average cost (both direct and indirect) per person for treating type 2 diabetes mellitus ranged from USD29.91 to USD237.38, direct costs ranged from USD106.53 to USD293.79, and indirect costs ranged from USD1.92 to USD73.4 per person per year. Hospitalization cost was the major contributor of direct costs followed by drug costs. Conclusion Type 2 diabetes mellitus imposes a considerable economic burden which most directly affects the patients in low and lower-middle income countries. There is enormous scope for adding research-based evidence that is methodologically sound to gain a more accurate estimation of cost and to facilitate comparison between studies. Electronic supplementary material The online version of this article (10.1186/s12913-018-3772-8) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink